Cancer Drug Uncertainty Affects Patient Decisions

New research finds that disclosing uncertainties about cancer treatments reduces patient willingness to take medications.

Updated on Oct. 16, 2026 in Cancer

Modern, minimalist clinical hallway with frosted glass partitions, bathed in soft, cool, diffused natural light. — New research shows that disclosing specific uncertainties about cancer medications significantly reduces patient trust and willingness to begin treatment. AI Illustration. Upload story photo >

Live Poll

Would you prefer to know all potential drug uncertainties before deciding to take a new medication?

A study of 6,272 U.S. adults indicates that awareness of drug uncertainties leads to a decreased perception of effectiveness and lower trust in cancer treatments. Participants showed a significantly lower likelihood of choosing a drug after learning about specific potential risks or data limitations.

Why it matters

Understanding how patients process information regarding treatment uncertainties is vital for improving medical transparency and informed consent. These findings suggest that communication strategies play a critical role in how individuals weigh the benefits and risks of life-altering cancer medications.

The study utilized 6,272 participants across two trials to measure decision-making shifts. Findings showed a 10.1 percentage point mean reduction in the willingness to take a drug when uncertainty was introduced.

The players

JAMA Internal Medicine

This is a peer-reviewed medical journal that publishes original research and clinical reviews relevant to internal medicine.

The details

Participants were tasked with rating their intent to take a medication before and after receiving information about five specific types of scientific uncertainty. The research highlights that specific details, such as unknown patient improvement metrics or a lack of race and ethnicity data in trials, resulted in a 14.1 and 12.8 percentage point decrease in adoption likelihood, respectively.

Participants were recruited for the clinical trials from May 9 to July 26, 2025.
The research findings were published in JAMA Internal Medicine on October 12, 2026.

The Big Picture

This study provides empirical evidence that suggests current communication standards for the FDA's patient medication guide requirements could be improved by integrating more transparent summaries of scientific uncertainty.

Patients may find that understanding the limitations of clinical trial data helps them engage in more meaningful conversations with their oncologists. By asking about the level of certainty regarding a drug's benefits, individuals can make treatment choices that better align with their personal risk tolerance.

The takeaway

Transparency about medical uncertainty is essential for maintaining patient trust in new oncology treatments. Clearer summaries of drug limitations may ultimately help bridge the communication gap between complex clinical data and patient expectations.